Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2–2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)
Mathias Rummel(Universitätsklinikum Gießen und Marburg), Juergen Barth(Justus-Liebig-Universität Gießen), Christina Balser(Philipps University of Marburg), Michael Sandherr, Ulrich von Gruenhagen(Praxis für Hämatologie und Onkologie), Ulrich Kaiser(University of Applied Sciences Landshut), Axel Hinke, N. Niederle(Klinikum Leverkusen), Lothar Mueller(Leibniz Centre for Agricultural Landscape Research), Harald Balló(Praxis für Hämatologie und Onkologie), Wolfram Brugger(University of Freiburg), Eckhart Weidmann(Krankenhaus Nordwest), Manfred Welslau(Klinikum Aschaffenburg), Julia Vereschagina(Justus-Liebig-Universität Gießen), Christoph Losem, Martina Stauch
Cited by 41
Related Papers
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
|European Journal of Cancer|2011|615
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML
|Blood|2010|485
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425